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Abstract
This article deals with the problem of interpreting health-related quality of life (HRQL) outcomes
in clinical trials. First, we will briefly describe how dichotomization and item response theory can
facilitate interpretation. Based on examples from the medical literature for the interpretation of
HRQL scores we will show that dichotomies may help clinicians understand information provided
by HRQL instruments in RCTs. They can choose thresholds to calculate proportions of patients
benefiting based on absolute scores or change scores. For example, clinicians interpreting clinical
trial results could consider the difference in the proportion of patients who achieve a mean score
of 50 before and after an intervention on a scale from 1 to 100. For the change score approach,
they could consider the proportion of patients who have changed by a score of 5 or more. Finally,
they can calculate the proportion of patients benefiting and transform these numbers into a number
needed to treat or natural frequencies. Second, we will describe in more detail an approach to the
interpretation of HRQL scores based on the minimal important difference (MID) and proportions.
The MID is the smallest difference in score in the outcome of interest that informed patients or
informed proxies perceive as important, either beneficial or harmful, and that would lead the
patient or clinician to consider a change in the management. Any change in management will depend
on the downsides, including cost and inconvenience, associated with the intervention. Investigators
can help with the interpretation of HRQL scores by determining the MID of an HRQL instrument
and provide mean differences in relation to the MID. For instance, for an MID of 0.5 on a seven
point scale investigators could provide the mean change on the instrument as well as the
proportion of patients with scores greater than the MID. Thus, there are several steps investigators
can take to facilitate this process to help bringing HRQL information closer to the bedside.
Background
This article deals with the problem of interpreting health-
related quality of life (HRQL) outcomes from clinical tri-
als. The alternative titles that we had in mind for this
paper exemplify the problem: "The great merit of simple-
minded dichotomies for clinicians" or even more provoc-
ative, "The great merit of dichotomies for simple-minded
clinicians." These possible titles reflect the fact that clini-
cians have difficulties understanding quality-of-life meas-
ures because of the numerous available instruments and
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their diversity in items, response options, lack of familiar
units, and approaches to aggregation. We propose that
dichotomies can help with understanding HRQL instru-
ments.
In this article we will offer some possible strategies based
on examples. First, we will briefly describe how dichot-
omization and Rasch analysis, a particular form of analy-
sis according to item response theory (IRT), can facilitate
interpretation [1,2]. We will describe how researchers can
improve the presentation of HRQL outcome measures
and how clinicians can use intuitive thresholds to inter-
pret HRQL outcomes. Clinicians can use thresholds that
either refer to an absolute score (e.g. clinicians can con-
sider patients above a certain score as having achieved the
outcome) or a change in score (e.g. clinicians can consider
patients' HRQL as having improved or deteriorated if they
achieve a certain change in score on an instrument of
interest). For the absolute score, imagine a trial using the
Short Form-36 (SF-36) HRQL instrument as the primary
outcome. Clinicians interpreting clinical trial results
could consider the proportion of patients who achieve a
mean score of 50 before and after an intervention. For the
change score approach, they could consider the propor-
tion patients who have changed by a score of 5 or more.
In the following text, we will describe these approaches
and provide additional examples from the medical litera-
ture. While we will provide examples for the use of item
response theory, we will not discuss details of the statisti-
cal methods. Interested readers should consult specialized
texts for an in-depth understanding.
Second, we will suggest an approach to the interpretation
of HRQL scores based on the minimal important differ-
ence (MID) [3-6]. The MID is the smallest difference in
score in the outcome of interest that informed patients or
informed proxies perceive as important, either beneficial
or harmful, and that would lead the patient or clinician to
consider a change in the management [3,6]. We place a
greater weight on the preferences of informed patients
than clinicians in studying the MID [6,7]. To further qual-
ify this definition of the MID, only if informed patients
cannot make decisions about the management of their
disease, or if patients prefer informed proxies to make
these decisions, would one consider the MID estimates of
informed proxies. In addition, any change in manage-
ment will depend on the downsides, including cost and
inconvenience, associated with the intervention.
How Do Investigators Present Health-Related Quality-of-
Life Information Currently?
To highlight the problem, we describe an example of the
failure to present HRQL in a transparent and understand-
able way to clinicians. In a trial including 553 patients
with psoriasis, a group of investigators evaluated the
impact on HRQL of alefacept, a fusion protein that inhib-
its T-cell activation and promotes apoptosis of CD2+ T
cells that play a role in psoriasis, on HRQL [8]. They used
the Dermatology Life Quality Index (DLQI), Dermatology
Quality of Life Scales (DQOLS), and SF-36. The authors
describe that alefacept significantly reduced (improved)
mean DLQI scores compared with the placebo. The
improvements were 4.4 points vs. 1.8 at 2 weeks just after
the last dose (P < 0.0001) and 3.4 vs. 1.4 at 12 weeks after
the last dose (P < 0.001). They further mention that a
group of patients who received two courses of alefacept
experienced additional enhancement of quality-of-life
measures during the second course.
In the authors' opinion, the data from the SF-36 survey
confirmed that alefacept had no negative impact on gen-
eral quality of life, because the SF-36 did not show impor-
tant changes. The authors then reached the conclusion
that alefacept improved quality of life in patients with
chronic plaque psoriasis and maintained this benefit for
at least 12 weeks following cessation of treatment. This
presentation of HRQL information is quite typical for tri-
als of this sort (the trial was sponsored by the developer of
alefacept). Unfortunately, most clinicians will have diffi-
culty understanding what an improvement of 4.4 vs 1.8 or
3.4 vs 1.4 means to their patients. Does it mean that
patients do feel substantially better or have noticed an
important change, or does it mean that the improvement
was small, not noticeable for patients, and statistically sig-
nificant only because of the large sample size? The answer
to this question is not clear because the authors do not
provide satisfactory guidance as to how important these
score changes are. However, the example should clarify
one of the fundamental problems of HRQL data: the fail-
ure to present the data in interpretable and transparent
manner. In the following paragraphs we will present pos-
sible solutions to these problems.
Discussion
Possible Solutions I – Dichotomized items
Possible solutions to the problem of clinicians' lack of
familiarity with HRQL scores exist. To focus on what is
called the content-based interpretation of results pro-
posed by Ware and Keller, let us take a look at the distri-
bution of the SF-36 scores of the Physical Function scale
based on the Medical Outcomes Study, a large study in the
U.S. [9]. Figure 1 shows the proportion of patients who
are able, according to scores on the SF-36, to walk a dis-
tance of one block (approximately 100 meters) without
difficulty.
Figure 1 shows dichotomized responses to the item in a
way that is meaningful. It also reveals differences across
levels of the scale in the score range of interest. Increasing
the score from 50 to 60 indicates that the proportion ofHealth and Quality of Life Outcomes 2006, 4:62 http://www.hqlo.com/content/4/1/62
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respondents able to walk a block increased from 50% to
79%. Clinicians could, thus, interpret a score of 50 as a
score that corresponds to approximately 50% of patients
being able to walk one block. An individual patient who
has a score of 50 would have a 50% chance of being able
to walk one block. If an intervention improved the score
to 60, there would now be a 79% chance, or a 29%
increase, of this patient's ability to walk one block.
Possible Solutions II – Item Response Theory
Another example of the use of content-based interpreta-
tion of HRQL measures is the use of the visual function 14
index (VF14) [10]. This instrument asks respondents to
rate the difficulties they have with their vision during per-
formance of 14 everyday activities. Respondents answer
on a five-points scale ranging from "no difficulty" to "una-
ble to do the activity," and scores are then expressed on a
0 (worst function) to 100 (best function) scale. Valderas
et al. used Rasch analysis based on item response theory
(IRT) to estimate the item difficulty – they utilized a score
on the item at which 50% of respondents can do the activ-
ity without difficulty [10]. Figure 2 indicates the scores on
the VF14 that correspond to 50% of respondents being
able to perform the described activity, ranked by impor-
tance or level of difficulty.
Figure 2 shows that a score of approximately 95 indicates
that 50% of respondents can drive without difficulty at
night in regard to their visual function. A score of 32 indi-
cates that 50% of respondents have no difficulty recogniz-
ing people when they are close. The authors could have
chosen a VF-14 score at which 25% of respondents have
no difficulty recognizing people when they are close or a
score at which 75% of respondents have no difficulty rec-
ognizing people when they are close. Using a cut-off of
50% simplifies interpretation because it implies a 1 to 1
chance.
Thus, the important contribution of IRT to the interpreta-
tion of HRQL scores is that it provides clinicians and
patients with guidance what they can expect from
respondents based on the entire score on a multi-item
This figure shows how clinicians can use thresholds that either refer to an absolute score, (e.g. clinicians can consider all  patients above a certain score as having achieved the outcome), or a change in score, (e.g. clinicians should consider patients'  HRQL as having improved or deteriorated if they achieve a certain change in score on an instrument of interest) Figure 1
This figure shows how clinicians can use thresholds that either refer to an absolute score, (e.g. clinicians can consider all 
patients above a certain score as having achieved the outcome), or a change in score, (e.g. clinicians should consider patients' 
HRQL as having improved or deteriorated if they achieve a certain change in score on an instrument of interest). It shows the 
proportion of patients who are able, according to scores on the SF-36, to walk a distance of one block (approximately 100 
meters) without difficulty. Increasing the score from 50 to 60 indicates that 29% more people state that they can walk without 
limitations. A score of 50 indicates that approximately 50% of patients are able to walk one block. An individual patient who 
has a score of 50 would have a 50% chance of being able to walk one block. If an intervention improved the score to 60, there 
would now be a 79% chance, or a 29% increase, of this patient's ability to walk one block.
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instrument. However, the IRT approach is restricted to
instruments with a clear gradient of the level of difficulty
across the instruments' items. It cannot be applied to situ-
ations when the response options there is no clear gradi-
ent in the severity of limitation or impairment associated
with the items. The VF-14 works well in this regard
because each item is more challenging than all lower
items. Being able to drive at night, for instance, requires
much better visual acuity than recognizing people even
when they are close. The IRT approach to interpretability
would not work for instruments in which this clear order-
ing does not exist.
Possible solution III – use of minimal important difference
Different methods to determine the MID exist. Anchor-
based methods rely on examining the associations
between scores on the instrument that is under investiga-
tion and an anchor, an independent measure of HRQL
that clinicians can easily interpret [11,12]. For instance,
investigators have used global ratings of change for
In this figure a score of 95 indicates that 50% of respondents can drive without difficulty during at night in regards to their vis- ual function Figure 2
In this figure a score of 95 indicates that 50% of respondents can drive without difficulty during at night in regards to their vis-
ual function. A score of 32 indicates that 50% of respondents have no difficulty recognizing people when they are close. This 
interpretation provides clinicians and patients with guidance what they can expect based on a score on a multi-item instrument. 
The approach is restricted to instruments with a clear gradient of severity across the instruments' items.
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within-patient estimates of the MID. Another method is
the use of between-patient ratings, that is, a comparison of
one patient with another [13]. Research suggests that for
three widely used HRQL instruments, the chronic respira-
tory questionnaire (CRQ), the asthma quality of life ques-
tionnaire (AQLQ) and the chronic heart failure
questionnaire (CHQ), the MID is 0.5 on the 7 point scale
[3-6].
However, two questions come to mind. First, does a group
mean change of 0.6 in response to a treatment on the 7-
point scale for the CRQ, AQLQ, or CHQ mean that all
patients benefit? Second, does a group mean change of 0.3
mean that no patient benefits? In the following sections
we will provide examples that will help answer these ques-
tions.
Absolute score difference
Let us examine the Rankin stroke scale, an instrument
widely used to measure dysfunction in patients who expe-
rienced a stroke [14]. The Rankin Stroke Scale has five lev-
els: (1) no symptoms; (2) minor handicap – restriction in
lifestyle, can look after self; (3) moderate handicap –
restriction in lifestyle preventing independent existence;
(4) moderately severe handicap – clearly preventing inde-
pendence, no constant attention needed; and (5) severe
handicap – requiring constant attention. A systematic
review of RCTs examined the effects of thrombolysis on
stroke using the Rankin Stroke Scale as an outcome [15].
The investigators used a threshold of a score of 2 (minor
handicap) versus 3 (moderate handicap) and examined
the proportion "dead or dependent" (dead or with a
Rankin score of 3 or more). The results indicated that
55.2% in the thrombolysis and 68.3% in the control
group experienced the outcome, representing a 42% odds
reduction or 13.1% risk difference (absolute risk reduc-
tion). This risk difference translates into an NNT (1/risk
difference) of 7 to 8 (or 130 fewer patients experiencing
the event for every 1000 treated). That is, for 7 to 8
patients treated with thrombolysis in acute stroke, 1 fewer
patient will be dead or dependent. This example shows
how investigators can facilitate the interpretation of RCTs
focusing on HRQL or functional outcomes by changing a
categorical variable into a binary variable.
Another example is that of the use of neurolytic coeliac-
plexus block (NCPB) versus systemic analgesic therapy
(SAT) alone in unresectable pancreatic cancer [16]. The
authors investigated the severity of pain using a 10-point
scale. In the first six weeks, the number of patients report-
This figure shows the results of an intervention that, on average, has no effect and is expressed as effect size (mean difference  divided by the standard deviation) Figure 3
This figure shows the results of an intervention that, on average, has no effect and is expressed as effect size (mean difference 
divided by the standard deviation). It is evident that while the mean indicates no effect, the effect is normally distributed around 
the mean.
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
-3   -2.5   -2   -1.5     -1 -0.5    0    0.5   1    1.5     2 2.5      3 
Effect Size
Intervention – no effectHealth and Quality of Life Outcomes 2006, 4:62 http://www.hqlo.com/content/4/1/62
Page 6 of 8
(page number not for citation purposes)
ing pain at an intensity of 5/10 or higher (moderate to
severe pain), was significantly lower in the NCPB group
(14% vs 40%) than in the SAT group. This result corre-
sponded to a risk difference of 26%, an NNT (1/risk dif-
ference) of approximately 4, or 260 fewer patients for
every 1000 treated who had pain that was moderate to
severe. Here, the investigators have converted a continu-
ous outcome into a binary outcome.
Change Score Difference
We will now examine examples of how clinicians can
interpret change score differences. Figure 3 shows the
results of an intervention that, on average, has no effect
and is expressed as effect size (we will refer to effect size
based on the standardized response mean calculated as
difference divided by the standard deviation of the change
score). It is evident that while the mean indicates no
effect, the effect is normally distributed around the mean.
Figure 4 shows the results of a hypothetical trial that com-
pares the effect size in a treatment group to a control
group after an effective intervention. The treatment group
experienced a large effect. The control group showed, on
average, a small improvement compatible with a placebo
effect. The effects are normally distributed and not every
patient improved; indeed, some deteriorated.
The vertical line shows the hypothetical MID for patients
participating in this trial. A certain proportion of patients
in the control group [labeled P(Imp|C)] show improve-
ment greater than the MID. In the treatment group, a
larger proportion [P(Imp|T)] of patients show improve-
This figure shows the results of a hypothetical trial that compares the effects size after an effective intervention in a treatment  group (T) to a control group (C) after an effective intervention Figure 4
This figure shows the results of a hypothetical trial that compares the effects size after an effective intervention in a treatment 
group (T) to a control group (C) after an effective intervention. The treatment group had experienced a large effect. The con-
trol group had experienced, on average, a small improvement compatible with a placebo effect. The effects are normally dis-
tributed and not every patient improved; indeed, some deteriorated. The vertical line shows the hypothetical MID for patients 
participating in this trial. A certain proportion of patients in the control group show improvement greater than the MID 
[labeled P(Imp|C), the area under the curve to the right of the MID line in the control group]. In the treatment group, a larger 
proportion [P(Imp|T),] of patients show improvement greater than the MID (the area under the curve to the right of the MID 
line in the group receiving therapy). The difference between these two proportions [P(Imp|T) - P(Imp|C), the difference in the 
two areas under the curve] is the proportion of patients who improved above the MID after accounting for placebo or control 
group effects.
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ment greater than the MID. The difference between these
two proportions [P(Imp|T) - P(Imp|C)] is the proportion
of patients who improved above the MID after accounting
for placebo or control group effects.
From this proportion one can easily calculate a risk differ-
ences or NNT. Norman et al showed a consistent relation
between effect size and NNTs across a wide range of plau-
sible specifications of the MID [17]. Table 1 presents the
relation between NNT and effect size.
Figure 5 shows a real world example of how clinicians can
interpret change score differences using the CRQ.
As we described above, the MID for the CRQ on each of
the four HRQL domains is 0.5. This example shows results
from a randomized controlled trial comparing intensive
respiratory rehabilitation to conventional care in patients
with moderate to severe chronic respiratory disease
(COPD) [18]. The lines depict change scores on the seven-
point CRQ dyspnea domain. Because HRQL in patients
with COPD deteriorates over time, the mean CRQ dysp-
nea score decreased (worse function) in the control group
after three months of observation. Patients in the rehabil-
itation group showed a small increase in CRQ scores. The
mean difference between the two groups was 0.6 (95%
confidence interval = 0.18 to 1.03). The figure indicates
Table 1: This table shows the number needed to treat (NNT) by effect size
Effect Size 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8
N N T 2 0 1 3 975544
This example shows results from a randomized controlled trial comparing intensive respiratory rehabilitation to conventional  care in patients with moderate to severe chronic respiratory disease Figure 5
This example shows results from a randomized controlled trial comparing intensive respiratory rehabilitation to conventional 
care in patients with moderate to severe chronic respiratory disease. The lines depict change scores on the seven-point CRQ 
dyspnea domain. Because HRQL in patients with COPD deteriorates over time, the mean CRQ dyspnea score decreased 
(worse function) in the control group after three months of observation. Patients in the rehabilitation group showed a small 
increase in CRQ scores. The mean difference between the two groups was 0.6 (95% confidence interval = 0.18 to 1.03). The 
figure indicates that a greater proportion of patients in the treatment compared to the control group had an improvement 
greater than the MID. One can calculate the proportion of patients improving in both groups that improve above or below any 
threshold.
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that a greater proportion of patients in the treatment com-
pared to the control group had an improvement greater
than the MID. One can calculate the proportion of
patients improving in both groups that improve above or
below any threshold.
Conclusion
These examples of the interpretation of HRQL scores dem-
onstrate that dichotomies may help the understanding of
information provided by HRQL instruments in RCTs.
There are several steps investigators can take to facilitate
this process. They can choose thresholds and dichotomize
responses on HRQL based on absolute scores or change
scores to facilitate interpretation. Second, they can deter-
mine the MID of an HRQL instrument and provide mean
differences and relate these to the MID. Finally, they can
use the dichotomized responses and the MID to calculate
the proportion of patients benefiting and transform these
numbers into NNTs and natural frequencies. Simple
dichotomies may bring HRQL information closer to the
bedside.
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